These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 37961928)
1. Effects of the HIV-1 maturation inhibitor GSK3640254 on QT interval in healthy participants. Zhang Y; Bush M; Yazdani P; Zhan J; Wen B; Bainbridge V; Wynne BR; Joshi S; Lataillade M Pharmacol Res Perspect; 2023 Dec; 11(6):e01151. PubMed ID: 37961928 [TBL] [Abstract][Full Text] [Related]
2. Open-label, drug-drug interaction study between the HIV-1 maturation inhibitor GSK3640254 and a metabolic probe cocktail in healthy participants. Zhang Y; Johnson M; Joshi S; Yazdani P; Zhan J; Wen B; Bainbridge V; Gartland M; Lataillade M Br J Clin Pharmacol; 2023 Jul; 89(7):2236-2245. PubMed ID: 36822839 [TBL] [Abstract][Full Text] [Related]
3. Phase IIa Proof-of-Concept Evaluation of the Antiviral Efficacy, Safety, Tolerability, and Pharmacokinetics of the Next-Generation Maturation Inhibitor GSK3640254. Spinner CD; Felizarta F; Rizzardini G; Philibert P; Mitha E; Domingo P; Stephan CJ; DeGrosky M; Bainbridge V; Zhan J; Dumitrescu TP; Jeffrey JL; Xu J; Halliday F; Gan J; Johnson M; Gartland M; Joshi SR; Lataillade M Clin Infect Dis; 2022 Sep; 75(5):786-794. PubMed ID: 34996113 [TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and tolerability of the maturation inhibitor GSK3640254 coadministered with darunavir/ritonavir and/or etravirine in healthy adults. Zhang Y; Joshi S; Yazdani P; Zhan J; Wen B; Bainbridge V; Ballesteros-Perez A; Gartland M; Lataillade M Br J Clin Pharmacol; 2024 Jan; 90(1):274-285. PubMed ID: 37621050 [TBL] [Abstract][Full Text] [Related]
5. Lack of effect of perampanel on QT interval duration: Results from a thorough QT analysis and pooled partial seizure Phase III clinical trials. Yang H; Laurenza A; Williams B; Patten A; Hussein Z; Ferry J Epilepsy Res; 2015 Aug; 114():122-30. PubMed ID: 26088895 [TBL] [Abstract][Full Text] [Related]
6. Ipragliflozin does not prolong QTc interval in healthy male and female subjects: a phase I study. Zhang W; Smulders R; Abeyratne A; Dietz A; Krauwinkel W; Kadokura T; Keirns J Clin Ther; 2013 Aug; 35(8):1150-1161.e3. PubMed ID: 23910665 [TBL] [Abstract][Full Text] [Related]
7. Combination of olanzapine and samidorphan has no clinically relevant effects on ECG parameters, including the QTc interval: Results from a phase 1 QT/QTc study. Sun L; Yagoda S; Xue H; Brown R; Nangia N; McDonnell D; Rege B; von Moltke L; Darpo B Prog Neuropsychopharmacol Biol Psychiatry; 2020 Jun; 100():109881. PubMed ID: 32004636 [TBL] [Abstract][Full Text] [Related]
8. Effect of Retosiban on Cardiac Repolarization in a Randomized, Placebo- and Positive-controlled, Crossover Thorough QT/QTc Study in Healthy Men and Women. Stier B; Fossler M; Liu F; Caltabiano S Clin Ther; 2015 Jul; 37(7):1541-54. PubMed ID: 26138866 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of the effects of bitopertin (RG1678) on cardiac repolarization: a thorough corrected QT study in healthy male volunteers. Hofmann C; Banken L; Hahn M; Swearingen D; Nagel S; Martin-Facklam M Clin Ther; 2012 Oct; 34(10):2061-71. PubMed ID: 22980315 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of the Effect of Selumetinib on Cardiac Repolarization: A Randomized, Placebo- and Positive-controlled Crossover QT/QTc Study in Healthy Subjects. Zhou D; So K; Dymond AW; Vik T; Al-Huniti N; Mariani G; Zorenyi G; Huang Y; Holmes V; Severin P; Rasmussen S; Martin P Clin Ther; 2016 Dec; 38(12):2555-2566. PubMed ID: 27837934 [TBL] [Abstract][Full Text] [Related]
11. GSK3640254 Is a Novel HIV-1 Maturation Inhibitor with an Optimized Virology Profile. Dicker I; Jeffrey JL; Protack T; Lin Z; Cockett M; Chen Y; Sit SY; Gartland M; Meanwell NA; Regueiro-Ren A; Drexler D; Cantone J; McAuliffe B; Krystal M Antimicrob Agents Chemother; 2022 Jan; 66(1):e0187621. PubMed ID: 34780263 [TBL] [Abstract][Full Text] [Related]
12. Thorough QT study of the effects of vildagliptin, a dipeptidyl peptidase IV inhibitor, on cardiac repolarization and conduction in healthy volunteers. He YL; Zhang Y; Serra D; Wang Y; Ligueros-Saylan M; Dole WP Curr Med Res Opin; 2011 Jul; 27(7):1453-63. PubMed ID: 21609207 [TBL] [Abstract][Full Text] [Related]
13. Thorough QT Study To Evaluate the Effect of Zoliflodacin, a Novel Therapeutic for Gonorrhea, on Cardiac Repolarization in Healthy Adults. Newman LM; Kankam M; Nakamura A; Conrad T; Mueller J; O'Donnell J; Osborn BL; Gu K; Saviolakis GA Antimicrob Agents Chemother; 2021 Nov; 65(12):e0129221. PubMed ID: 34606332 [TBL] [Abstract][Full Text] [Related]
14. A Randomized Trial to Assess the Effect of Doravirine on the QTc Interval Using a Single Supratherapeutic Dose in Healthy Adult Volunteers. Khalilieh SG; Yee KL; Fan L; Liu R; Heber W; Dunzo E; Triantafyllou I; Hussaini A; Iwamoto M Clin Drug Investig; 2017 Oct; 37(10):975-984. PubMed ID: 28785879 [TBL] [Abstract][Full Text] [Related]
15. Effects of Therapeutic and Supratherapeutic Doses of Siponimod (BAF312) on Cardiac Repolarization in Healthy Subjects. Shakeri-Nejad K; Aslanis V; Veldandi UK; Mooney L; Pezous N; Brendani B; Juan A; Allison M; Perry R; Legangneux E Clin Ther; 2015 Nov; 37(11):2489-2505.e2. PubMed ID: 26519230 [TBL] [Abstract][Full Text] [Related]
16. Effects of triclabendazole and its metabolite exposure on the heart-rate-corrected QT intervals: A randomized, placebo- and positive-controlled thorough QT study in healthy individuals. Prince WT; Venishetty VK; Lecot J; Shakeri-Nejad K; Gray C; Taylor A; Iyer GR; Zack J Clin Transl Sci; 2023 Oct; 16(10):1758-1767. PubMed ID: 37688315 [TBL] [Abstract][Full Text] [Related]
17. A Phase I, Randomized, Double-Blinded, Placebo- and Moxifloxacin-Controlled, Four-Period Crossover Study To Evaluate the Effect of Gepotidacin on Cardiac Conduction as Assessed by 12-Lead Electrocardiogram in Healthy Volunteers. Hossain M; Zhou M; Tiffany C; Dumont E; Darpo B Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28223381 [TBL] [Abstract][Full Text] [Related]
18. A thorough QT study to evaluate the effects of therapeutic and supratherapeutic doses of delafloxacin on cardiac repolarization. Litwin JS; Benedict MS; Thorn MD; Lawrence LE; Cammarata SK; Sun E Antimicrob Agents Chemother; 2015; 59(6):3469-73. PubMed ID: 25845864 [TBL] [Abstract][Full Text] [Related]
19. No QTc Prolongation With Zanubrutinib: Results of Concentration-QTc Analysis From a Thorough QT Study in Healthy Subjects. Mu S; Darpo B; Tang Z; Novotny W; Tawashi M; Xue H; Willett M; Lin L; Sahasranaman S; Ou YC Clin Transl Sci; 2020 Sep; 13(5):923-931. PubMed ID: 32144955 [TBL] [Abstract][Full Text] [Related]
20. Vericiguat: A Randomized, Phase Ib, Placebo-Controlled, Double-Blind, QTc Interval Study in Patients with Chronic Coronary Syndromes. Böttcher M; Düngen HD; Corcea V; Donath F; Fuhr R; Gal P; Mikus G; Trenk D; Coenen M; Pires PV; Maschke C; Aliprantis AO; Besche N; Becker C Am J Cardiovasc Drugs; 2023 Mar; 23(2):145-155. PubMed ID: 36633816 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]